Overview

A Study Investigating the Efficacy, Safety, and PK Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe AD

Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of ANB020 in subjects with atopic dermatitis (AD).
Phase:
Phase 2
Details
Lead Sponsor:
AnaptysBio, Inc.